Publications by authors named "Robert Glanzman"

Claim this Profile
C
CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.

JAMA· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials.
Jimin Ren, Richard B Dewey, Austin Rynders, Jacob Evan, Jeremy Evan, Robert Glanzman

J Nanobiotechnology· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials.
Jimin Ren, Richard B Dewey, Austin Rynders, Jacob Evan, Jeremy Evan, Robert Glanzman

J Nanobiotechnology· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension.
Steve Vucic, Parvathi Menon, William Huynh, Colin Mahoney, Karen S Ho, Robert Glanzman

EClinicalMedicine· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
Hans-Peter Hartung, Tobias Derfuss, Bruce Ac Cree, Maria Pia Sormani, Krzysztof Selmaj, Robert Glanzman

Mult Scler· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment.
Steve Vucic, Toby A Ferguson, Catherine Cummings, Michael T Hotchkin, Angela Genge, Robert Glanzman

Muscle Nerve· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of an evidence-based, out-patient treatment strategy for COVID-19: Multidisciplinary medical practice principles to prevent severe disease.
Elliot M Frohman, Nicole R Villemarette-Pittman, Adriana Rodriguez, Robert Glanzman, Sarah Rugheimer

J Neurol Sci· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study protocol of RESCUE-ALS: A Phase 2, andomised, double-blind, placebo-controlled study in arly ymptomatic amyotrophic lateral sclerosis patients to assess bioenergetic atalysis with CNM-A8 as a mechanism to slow diseas progression.
Steve Vucic, Matthew C Kiernan, Parvathi Menon, William Huynh, Austin Rynders, Robert Glanzman

BMJ Open· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prehistoric enemies within: The contribution of human endogenous retroviruses to neurological diseases. Meeting report: "Second International Workshop on Human Endogenous Retroviruses and Disease", Washington DC, March 13th and 14th 2017.
David Kremer, Robert Glanzman, Anthony Traboulsee, Avindra Nath, Laurent Groc

Mult Scler Relat Disord· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design.
Francois Curtin, Herve Porchet, Robert Glanzman, Hans Martin Schneble, Virginie Vidal

Mult Scler Relat Disord· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EDSS variability before randomization may limit treatment discovery in primary progressive MS.
Jiameng Zhang, Emmanuelle Waubant, Gary Cutter, Jerry S Wolinsky, Robert Glanzman

Mult Scler· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On being a neurologist in industry.
David Leppert, Robert Glanzman

Ann Neurol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Ludwig Kappos, David Li, Peter A Calabresi, Paul O'Connor, Amit Bar-Or, Robert Glanzman

Lancet· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of optical coherence tomography in multiple sclerosis: expert panel consensus.
Robert C Sergott, Elliot Frohman, Robert Glanzman, Ahmad Al-Sabbagh,

J Neurol Sci· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of gabapentin for postherpetic neuralgia: results of two randomized, placebo-controlled studies.
Brett R Stacey, Robert L Glanzman

Clin Ther· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials.
Miroslav Backonja, Robert L Glanzman

Clin Ther· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis